Anixa Biosciences (ANIX) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Anixa Biosciences (ANIX) has outperformed Rani Therapeutics (RANI) over the past year, losing 34.9% versus a loss of 60.9%. Over five years, ANIX leads with a -38.5% price change compared with -96.5% for RANI. Anixa Biosciences is the larger company by market cap ($92.8 million vs $90.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | RANI |
|---|---|---|
| Share price | $2.67 | $0.6406 |
| Market cap | $92.82M | $90.02M |
| 1-day change | -3.96% | -5.79% |
| YTD return | -14.42% | -52.55% |
| 1-year return | -34.88% | -60.94% |
| 5-year return | -38.48% | -96.54% |
| EPS (TTM) | $-0.32 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | $-10.93M | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $5.46 | $3.87 |
| 52-week low | $2.32 | $0.613 |
| Distance from 52-week high | -51.10% | -83.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +265.17% | +1023.95% |
| Average volume | 296.48K | 720.45K |
| Shares outstanding | 34.76M | 115.42M |
| Employees | 4 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIX has outperformed RANI by 26.1 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ANIX vs RANI FAQ
Which is bigger, Anixa Biosciences or Rani Therapeutics?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $92.82M compared with $90.02M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, ANIX or RANI?
ANIX returned -34.88% over the past 12 months, compared with -60.94% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.